Panbela exceeds 50% enrollment for aspire trial in pancreatic cancer, exceeding anticipated timelines with accelerated momentum

Minneapolis, jan. 25, 2024 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has reached 50% enrollment for its aspire global clinical trial in the first-line treatment of metastatic pancreatic cancer. aspire is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. detailed information on the trial can be located at  https://clinicaltrials.gov/ct2/show/nct05254171  .
PBLA Ratings Summary
PBLA Quant Ranking